Monte Rosa Therapeutics Inc

Insider sales at Monte Rosa Therapeutics signal possible over‑valuation and a short‑term focus, urging investors to weigh biotech risk against future innovation.

CEO sells 5,466 Monte Rosa shares at $23.88: liquidity or confidence? Insider trades reveal no major downside, but highlight ongoing capital‑raising plans.